The laboratory of coagulation: A review of present laboratory techniques

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 1, 1998, Pages 83-88

  Khan, Fauzia ^a   Michael Snyder, L ^a,b   Liberto Pechet, M D ^a,b  

^a Medical Center   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Activated coagulation time; Blood coagulation tests; Partial thromboplastin time; Prothrombin time

Indexed keywords

AUTOMATION; BLOOD CLOTTING TEST; LABORATORY TEST; METHODOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031884701     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008813924612     Document Type: Review

References (33)

1. Morawitz P. The Chemistry of blood coagulation. Ergebn Physiol 1905;4:307-422. Reprinted in Hartmann RC, Guenther PF (trans), Springfield, Illinois, Charles C Thomas, 1958.
2. Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501-511.
3. Quick AJ. The development and use of the prothrombin tests. Circulation 1959;19:92-96.
4. Quick, AJ. On the constitution of prothrombin. Am J Physiol 1943:140:212-220.
5. Owren PA. The coagulation of Blood. Investigations on a new clotting factor. Acta Med Scand Suppl 1947;194:1-327.
6. Alexander B, Goldstein R, Landwehr G, et al. Congenital SPCA deficiency: A hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951;30:596-608.
7. Hougie C, Barrow EM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogenous group heretofore called "stable factor" (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 1957;36: 485-496.
8. Biggs R, Douglas AS. The thromboplastin generation test. J Clin Pathol 1953;6:23-29.
9. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for antihemophilic factor assay procedure. J Lab Clin Med 1953;41:637-647.
10. Waldman R, Abraham JB. Fitzgerald fator, a heretofore unrecognised coagulation factor. Blood 1974;44:949-951.
11. Hathaway WE, Belhasen LP, Hathway HS. Evidence for a new thromboplastin factor. Case report, coagulation studies and physicochemical properties. Blood 1965;26:521-532.
12. Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913;145:495-503.
13. Hattersley PG. Activated clotting time of whole blood. JAMA 1966;196:436-440.
14. Simko RJ, Tsung FEW, Stanek EJ. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. The Annals of Pharmacotherapy. 1995;29:1015-1021.
15. Chapell P, Chatalain B, Leclerq R, Lust A, Masure R, Arnout J. Quality Control in Haemostasis. Acta Clinica Biologica 1992;47.5:308-318.
16. Palmer RN, Gralnick HR. Cold induced contact surface activation of the prothrombin time in whole blood. Blood 1981; 59:38-42.
17. Musgrave KA, Triplett DA. Internal quality assurance in blood coagulation. Recent advances in blood coagulation. Churchill Livingstone Edinburgh: 1985:pp 235-250.
18. Thomson JM. Pre-test variables in blood coagulation testing. Blood coagulation and haemostasis. A practical guide. Third edition. Churchill Livingstone, Edinburgh. 1985:340-369.
19. Paterson P, Gottfried EL. The effects of inaccurate blood samples volume on prothrombin time (PT) and activated partial thromboplastin time (aPTT). Thromb Haemost 1982;47: 101-103.
20. Leaning, Ansell. Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient self management. J Thromb and Thrombolysis. 1996; 3:4:377-383.
21. Macik, Gail B. Designing a Point-of-care Program for Coagulation Testing. Arch Pathol Lab Med 1995;119:929-938.
22. Kitchen S, Jenning I, Wood TAL, Preston FE, on behalf of the Steering Committee of the UK National Quality Assessment Scheme for Blood Coagulation, Royal Hallamshire Hosp, Sheffield UK. J Clin Pathol 1996;49:10-14.
23. Jensen R. Antiphospholipid Antibody Syndrome Diagnosis. Clinical Hemostasis Review. 1996;10:3:1-5.
24. Pakulti, Harlene S. Coagulation question and comments. Clinical Hemostasis Review. 1996;10:4:17.
25. Kitchen S. Prolonged Activated Partial Thromboplastin Time of Unknown Etiology: A Prospective Study of 100 Consecutive Cases Referred for Consultation. Am J Haematol 1988;27:38-45.
26. st Report, Tech Rep Ser. 1981;658:185-205.
27. Jensen R. Principles of antigenic and functional assays in hemostasis. Clinical Hemostasis Review. 1996;10:4:1-4.
28. Owen C. Historical account of tests of hemostasis. Am J Clin Pathol 1990;93:(suppl 1):s3-8.
29. Triplett DA. New development in diagnostic coagulation testing. New advances in hemostasis for transfusion medicine. Arlington, VA: American Association of Blood Banks 1990;17-25.
30. Exne, Burbridge, Power, Rickard, et al. An evaluation of currently available methods for plasma fibrinogen. Am J Clin Pathol 1979;71:521-527.
31. Funk C, Gmur J, Herald R, et al. Reptilase R® a new reagent in blood coagulation. Br J Haematol 1971;21:43-52.
32. Mackworth-Young C. Antiphospholipid syndrome. A treatable cause of recurrent pregnancy loss. BMJ 1997;314:p 249.
33. Kasper CK, Aledort LM, Counts J, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:869-872.